Cyclophosphamide and Embolism arterial - a phase IV clinical study of FDA data

Summary:

Embolism arterial is reported as a side effect among people who take Cyclophosphamide (cyclophosphamide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Prednisone, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Embolism arterial when taking Cyclophosphamide. It is created by eHealthMe based on reports of 185,094 people who have side effects when taking Cyclophosphamide from the FDA, and is updated regularly.

What is Cyclophosphamide?

Cyclophosphamide has active ingredients of cyclophosphamide. It is often used in multiple myeloma. eHealthMe is studying from 185,240 Cyclophosphamide users. Check the latest studies of Cyclophosphamide.

What is Embolism arterial?

Embolism arterial (blood clot that has travelled through your arteries and become stuck) is found to be associated with 217 drugs and 411 conditions by eHealthMe. Check the latest studies of Embolism arterial.

On Jul, 13, 2026

185,094 people reported to have side effects when taking Cyclophosphamide.
Among them, 29 people (0.02%) have Embolism arterial.

Could Cyclophosphamide cause Embolism arterial?

Among these 29 people:

How long have people been on Cyclophosphamide when they have Embolism arterial? *

What is the gender of people who have Embolism arterial when taking Cyclophosphamide? *

female: 40.91 %
male: 59.09 %

What is the age of people who have Embolism arterial when taking Cyclophosphamide? *

What are other drugs people take besides Cyclophosphamide? *

What are other side effects people have besides Embolism arterial? *

Sepsis (a severe blood infection that can lead to organ failure and death): 6 people, 20.69%
Peripheral Ischaemia (impaired circulation to an extremity): 6 people, 20.69%
Delirium (wild excitement): 6 people, 20.69%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 5 people, 17.24%
Limb Amputation (loss of leg): 5 people, 17.24%
Fever: 5 people, 17.24%
Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 5 people, 17.24%
Respiratory Tract Infection: 5 people, 17.24%
Diarrhea: 5 people, 17.24%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 13.79%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 27.59%
Bone Marrow Conditioning Regimen: 6 people, 20.69%
Blood Catecholamines Increased: 6 people, 20.69%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 6.90%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 1 person, 3.45%
Lymphoma (cancer that begins in immune system cells): 1 person, 3.45%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 1 person, 3.45%
Hiv Infection: 1 person, 3.45%
Herpes Virus Infection: 1 person, 3.45%
Febrile Neutropenia (fever with reduced white blood cells): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Cyclophosphamide and have Embolism arterial?

- Check whether Embolism arterial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyclophosphamide:

Cyclophosphamide (185,240 reports)

Browse all side effects of Cyclophosphamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism arterial:

Embolism arterial (217 drugs)

Browse all the conditions that are associated with Embolism arterial:

Embolism arterial (411 conditions)

Related publications that referenced our studies

Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .
Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on cyclophosphamide (the active ingredients of Cyclophosphamide) and Cyclophosphamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.